Author Archives: Mark McCarty

FDA’s off-label dilemma

As is widely known, the FDA is facing a change in leadership and has inked a memorandum staking out the agency’s current position on the off-label promotion problem. Despite the continued vetting of the problem by the agency, the memo…

FacebookTwitterGoogle+Share

Hyperventilation; Reaction to the Cures Act

  There may be someone on the dark side of the Moon that hasn’t heard about the Senate vote for the 21st Century Cures Act, but everyone else certainly has. One might have expected the reaction to the Cures bill…

FacebookTwitterGoogle+Share

Device flight round trips, and other matters

Never a dull moment in the world of medical devices and the Food and Drug Administration, is there? Sometimes the FDA is on the march, other times it seems the agency is about to be eclipsed by other forces. Don’t…

FacebookTwitterGoogle+Share

Loose the clown posse; Uncle Sam has cancer fever

You have to hand it to the cancer lobby. It really has the U.S. federal government wrapped around its little finger. Some will say I’m overstating the case, but is that really a solid argument? Let’s examine the evidence. Mortality,…

FacebookTwitterGoogle+Share

ACC 2016: All aboard the TAVR train

The Windy City really lived up to its name during the course of ACC 2016, didn’t it? It was also interesting to hear the recording on the subway stating that gambling is not allowed on the trains. Who knew? ACC…

FacebookTwitterGoogle+Share

To IVUS or not to IVUS

Everyone has heard about the FDA advisory hearing for the Absorb scaffold by Abbott Vascular, but to recap, one of the issues that came up in connection with the trial data for the Absorb was the association between coronary artery…

FacebookTwitterGoogle+Share

Abbott’s dilemma; Absorbing the Absorb

Now that Abbott Vascular has pulled out a resounding win at an FDA advisory committee for its Absorb bioresorbable scaffold, it’s time to ask what the coverage and reimbursement pictures look like. The coverage part looks easy – perhaps easier…

FacebookTwitterGoogle+Share

FDA’s thumb on the scale

It’s often interesting to see and hear the things that go on at FDA advisory hearings, and the Feb. 18 hearing for leadless pacemakers proved to be no exception. I’ll admit at the outset that I’ve always been of the…

FacebookTwitterGoogle+Share

POTUS, cancer and shooting for the moon

It was interesting to hear the President become archly ambitious about the oncological equivalent of a moonshot during his most recent State of the Union address. The President said veep Joe Biden would take the lead on an effort to…

FacebookTwitterGoogle+Share

FDA detention and other feel-good stories

Device makers like to grouse about FDA, but they’re not the only ones who feel they have an axe to grind. Recent warning letters suggest the agency is more frequently making use of detention to deal with violative products of…

FacebookTwitterGoogle+Share

Marketo